Breaking News, Collaborations & Alliances

Trenchant BioSystems, Invetech Sign Nonbinding Pact to Advance Automated CGT Manufacturing Platform

The alliance is focused on reducing CGT manufacturing times.

Author Image

By: Charlie Sternberg

Associate Editor

Trenchant BioSystems Inc., a developer of manufacturing platforms for gene‑modified cell therapies, has signed a nonbinding letter of intent with Invetech to form a strategic alliance aimed at advancing Trenchant’s AutoCell system from a semi‑automated prototype to a fully automated commercial product. The agreement outlines plans for Invetech to conduct a technical review of Trenchant’s existing AutoCell Alpha prototype. A definitive partnership contract is expected to follow the review. Ear...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters